Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2019 Jul 19

PMID 31315954

Citations 58

Authors

Barbara A Brown-Elliott

Gail L Woods

Affiliations

Soon will be listed here.

Abstract

Recommendations for first-line and second-line drug testing and organism group, specific methodologies, and reporting recommendations have been addressed by the Clinical and Laboratory Standards Institute (CLSI) and are important in the selection of appropriate antimicrobial treatment regimens for nontuberculous mycobacteria (NTM) disease. This review also includes recent information on new antimicrobials proposed for the treatment of NTM but not yet addressed by the CLSI and molecular (gene sequencing) methods associated with the detection of antimicrobial resistance of two major therapeutic antimicrobials, clarithromycin and amikacin.

Citing Articles

Diagnostics, resistance and clinical relevance of non-tuberculous mycobacteria unidentified at the species level by line probe assays: a bi-national study.

Dohal M, Wetzstein N, Hromadkova M, Masiarova S, Rasmussen E, Kunc P Ann Clin Microbiol Antimicrob. 2025; 24(1):14.

PMID: 39962513 PMC: 11834575. DOI: 10.1186/s12941-025-00781-z.

Disseminated infection in an immunocompromised adult: An uncommon etiology of skin infection.

Amare B, Mangano A, Sarker M, Adhikari S IDCases. 2025; 39():e02132.

PMID: 39810811 PMC: 11732071. DOI: 10.1016/j.idcr.2024.e02132.

Susceptibility Patterns in Clinical Isolates of Complex from a Hospital in Southern Spain.

Gonzalez Martinez A, Aguilera M, Tarrino M, Alberola A, Reguera J, Sampedro A Microorganisms. 2025; 12(12.

PMID: 39770815 PMC: 11679255. DOI: 10.3390/microorganisms12122613.

Deep learning-based prediction of chemical accumulation in a pathogenic mycobacterium.

Sullivan M, Rubin E bioRxiv. 2025; .

PMID: 39764009 PMC: 11702553. DOI: 10.1101/2024.12.15.628588.

Treatment outcomes in NTM-PD in a high TB burden context.

Kang S, Schmidt J, Chen I, Tiberi S IJTLD Open. 2024; 1(12):547-555.

PMID: 39679205 PMC: 11636495. DOI: 10.5588/ijtldopen.24.0413.

References

Wallace Jr R, Brown-Elliott B, Ward S, Crist C, MANN L, Wilson R . Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001; 45(3):764-7. PMC: 90370. DOI: 10.1128/AAC.45.3.764-767.2001. View

Griffith D, Brown-Elliott B, Wallace Jr R . Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis. 2003; 37(9):1178-82. DOI: 10.1086/378742. View

Nash K, Andini N, Zhang Y, Brown-Elliott B, Wallace Jr R . Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother. 2006; 50(10):3476-8. PMC: 1610084. DOI: 10.1128/AAC.00402-06. View

Griffith D, Aksamit T, Brown-Elliott B, Catanzaro A, Daley C, Gordin F . An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4):367-416. DOI: 10.1164/rccm.200604-571ST. View

Nash K, Brown-Elliott B, Wallace Jr R . A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009; 53(4):1367-76. PMC: 2663066. DOI: 10.1128/AAC.01275-08. View

Shen G, Wu B, Hu S, Lin C, Wu K, Chen J . High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents. 2010; 35(4):400-4. DOI: 10.1016/j.ijantimicag.2009.12.008. View

Lindeboom J, Bruijnesteijn van Coppenraet L, van Soolingen D, Prins J, Kuijper E . Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev. 2011; 24(4):701-17. PMC: 3194825. DOI: 10.1128/CMR.00020-11. View

Brown-Elliott B, Nash K, Wallace Jr R . Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012; 25(3):545-82. PMC: 3416486. DOI: 10.1128/CMR.05030-11. View

Brown-Elliott B, Iakhiaeva E, Griffith D, Woods G, Stout J, Wolfe C . In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013; 51(10):3389-94. PMC: 3811650. DOI: 10.1128/JCM.01612-13. View

10.

Hanson K, Slechta E, Muir H, Barker A . Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing?. J Clin Microbiol. 2014; 52(5):1705-7. PMC: 3993676. DOI: 10.1128/JCM.03464-13. View

11.

OBrien D, Jenkin G, Buntine J, Steffen C, McDonald A, Horne S . Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Med J Aust. 2014; 200(5):267-70. DOI: 10.5694/mja13.11331. View

12.

Brown-Elliott B, Hanson K, Vasireddy S, Iakhiaeva E, Nash K, Vasireddy R . Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group, based on in vitro clarithromycin susceptibility. J Clin Microbiol. 2015; 53(3):875-8. PMC: 4390626. DOI: 10.1128/JCM.02936-14. View

13.

Brown-Elliott B, Vasireddy S, Vasireddy R, Iakhiaeva E, Howard S, Nash K . Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol. 2015; 53(4):1211-5. PMC: 4365201. DOI: 10.1128/JCM.02950-14. View

14.

Buckwalter S, Olson S, Connelly B, Lucas B, Rodning A, Walchak R . Evaluation of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Mycobacterium species, Nocardia species, and Other Aerobic Actinomycetes. J Clin Microbiol. 2015; 54(2):376-84. PMC: 4733196. DOI: 10.1128/JCM.02128-15. View

15.

Olivier K, Griffith D, Eagle G, McGinnis 2nd J, Micioni L, Liu K . Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2016; 195(6):814-823. PMC: 5363966. DOI: 10.1164/rccm.201604-0700OC. View

16.

Brown-Elliott B, Philley J, Griffith D, Thakkar F, Wallace Jr R . In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex. Antimicrob Agents Chemother. 2016; 61(2). PMC: 5278735. DOI: 10.1128/AAC.01798-16. View

17.

Coelho R, Hanna R, Flagg A, Stempak L, Ondrejka S, Procop G . Mycobacterium genavense-induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature. Transpl Infect Dis. 2017; 19(2). DOI: 10.1111/tid.12656. View

18.

Brown-Elliott B, Wallace Jr R . Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria. J Clin Microbiol. 2017; 55(6):1747-1754. PMC: 5442531. DOI: 10.1128/JCM.00274-17. View

19.

Body B, Beard M, Slechta E, Hanson K, Barker A, Babady N . Evaluation of the Vitek MS v3.0 Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry System for Identification of Mycobacterium and Nocardia Species. J Clin Microbiol. 2018; 56(6). PMC: 5971548. DOI: 10.1128/JCM.00237-18. View

20.

Griffith D, Eagle G, Thomson R, Aksamit T, Hasegawa N, Morimoto K . Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018; 198(12):1559-1569. DOI: 10.1164/rccm.201807-1318OC. View